These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20864186)

  • 1. Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.
    Perez-Garmendia R; Ibarra-Bracamontes V; Vasilevko V; Luna-Muñoz J; Mena R; Govezensky T; Acero G; Manoutcharian K; Cribbs DH; Gevorkian G
    J Neuroimmunol; 2010 Dec; 229(1-2):248-55. PubMed ID: 20864186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits.
    Acero G; Manoutcharian K; Vasilevko V; Munguia ME; Govezensky T; Coronas G; Luz-Madrigal A; Cribbs DH; Gevorkian G
    J Neuroimmunol; 2009 Aug; 213(1-2):39-46. PubMed ID: 19545911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
    Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
    Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of N-terminally truncated pyroglutamate amyloid-β in cholesterol-enriched diet-fed rabbit and AD brain.
    Perez-Garmendia R; Hernandez-Zimbron LF; Morales MA; Luna-Muñoz J; Mena R; Nava-Catorce M; Acero G; Vasilevko V; Viramontes-Pintos A; Cribbs DH; Gevorkian G
    J Alzheimers Dis; 2014; 39(2):441-55. PubMed ID: 24240639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.
    Perez-Garmendia R; Gevorkian G
    Curr Neuropharmacol; 2013 Sep; 11(5):491-8. PubMed ID: 24403873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival.
    Russo C; Violani E; Salis S; Venezia V; Dolcini V; Damonte G; Benatti U; D'Arrigo C; Patrone E; Carlo P; Schettini G
    J Neurochem; 2002 Sep; 82(6):1480-9. PubMed ID: 12354296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.
    Gonzalez-Castro R; Acero Galindo G; García Salcedo Y; Uribe Campero L; Vazquez Perez V; Carrillo-Tripp M; Gevorkian G; Gomez Lim MA
    Inflammopharmacology; 2018 Jun; 26(3):817-827. PubMed ID: 29094307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
    Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA
    J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.
    Sullivan CP; Berg EA; Elliott-Bryant R; Fishman JB; McKee AC; Morin PJ; Shia MA; Fine RE
    Neurosci Lett; 2011 Nov; 505(2):109-12. PubMed ID: 22001577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
    Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer's disease.
    Bakrania P; Hall G; Bouter Y; Bouter C; Beindorff N; Cowan R; Davies S; Price J; Mpamhanga C; Love E; Matthews D; Carr MD; Bayer TA
    Mol Psychiatry; 2022 Feb; 27(2):840-848. PubMed ID: 34776512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits.
    Tekirian TL; Saido TC; Markesbery WR; Russell MJ; Wekstein DR; Patel E; Geddes JW
    J Neuropathol Exp Neurol; 1998 Jan; 57(1):76-94. PubMed ID: 9600199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.
    Gunn AP; Masters CL; Cherny RA
    Int J Biochem Cell Biol; 2010 Dec; 42(12):1915-8. PubMed ID: 20833262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.
    Cynis H; Frost JL; Crehan H; Lemere CA
    Mol Neurodegener; 2016 Jun; 11(1):48. PubMed ID: 27363697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
    Moretto N; Bolchi A; Rivetti C; Imbimbo BP; Villetti G; Pietrini V; Polonelli L; Del Signore S; Smith KM; Ferrante RJ; Ottonello S
    J Biol Chem; 2007 Apr; 282(15):11436-45. PubMed ID: 17267402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.
    Antonios G; Saiepour N; Bouter Y; Richard BC; Paetau A; Verkkoniemi-Ahola A; Lannfelt L; Ingelsson M; Kovacs GG; Pillot T; Wirths O; Bayer TA
    Acta Neuropathol Commun; 2013 Sep; 1():56. PubMed ID: 24252153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.